

Brain Derived Basic Fibroblast Growth Factor (1-24)

Cat. No.:	HY-P3601	
CAS No.:	211362-85-5	
Molecular Formula:	$C_{118}H_{173}N_{31}O_{33}$	
Molecular Weight:	2553.82	PALPEDGGSGAFPPGHFKDKPKRLY
Sequence Shortening:	PALPEDGGSGAFPPGHFKDKPKRLY	
Target:	Bacterial; HBV	
Pathway:	Anti-infection	
Storage:	Sealed storage, away from moisture and light	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (39.16 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		0.3916 mL	1.9579 mL	3.9157 mL
	5 mM		0.0783 mL	0.3916 mL	0.7831 mL
	10 mM		0.0392 mL	0.1958 mL	0.3916 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research^[1].

In Vitro

Brain Derived Basic Fibroblast Growth Factor (1-24) (10 µg/mL; 12 h) inhibits the growth of *Streptococcus pneumoniae*^[1].
 Brain Derived Basic Fibroblast Growth Factor (1-24) (10 µg/mL; 6 d) inhibits HBV replication of HepG2-2.2.15 cells^[1].
 Brain Derived Basic Fibroblast Growth Factor (1-24) (10 µg/mL; 22 h) inhibits the migration of human endothelial cell^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	<i>Streptococcus pneumoniae</i>
Concentration:	10 µg/mL

Incubation Time:	12 hours
Result:	Inhibited by 100% the growth of Streptococcus pneumoniae.
RT-PCR ^[1]	
Cell Line:	HepG2-2.2.15 cells
Concentration:	10 µg/mL
Incubation Time:	6 days
Result:	Inhibited by 31.4% HBV replication as compared to the virus control infection.
Cell Migration Assay ^[1]	
Cell Line:	Human endothelial cells (HUVEC)
Concentration:	10 µg/mL
Incubation Time:	22 hours
Result:	Inhibited by 17% the migration of human endothelial cells

REFERENCES

[1]. Dorian Bevec, et al. Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection. WO2009039980A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA